论文部分内容阅读
目的观察肾康注射液与前列地尔注射液合用治疗糖尿病性肾病IV期的临床疗效。方法将该院2014年8月—2016年9月收治的住院的糖尿病性肾病IV期患者75例随机分为2组,A组为前列地尔注射液常规治疗组,共38例;B组为肾康注射液及前列地尔注射液治疗组,共37例。通过治疗前后观察患者尿微量白蛋白、24 h尿蛋白定量及血肌酐3项指标。结果两组治疗均可改善糖尿病肾病患者的症状及各项指标,且B组与A组对比发现临床各项指标改善方面差异有统计学意义(P<0.05)。结论在治疗糖尿病性肾病IV期患者联合使用前列地尔注射液及肾康注射液具有明显的治疗效果。
Objective To observe the clinical efficacy of Shenkang injection combined with alprostadil injection in the treatment of stage Ⅳ diabetic nephropathy. Methods Seventy-five patients with stage IV diabetic nephropathy hospitalized from August 2014 to September 2016 in our hospital were randomly divided into two groups. A group was treated with alprostadil injection routinely, 38 cases in total. Shenkang injection and alprostadil injection treatment group, a total of 37 cases. Before and after treatment, the urinary albumin, 24 h urinary protein and 3 indexes of serum creatinine were observed. Results Both groups could improve the symptoms and indexes of patients with diabetic nephropathy, and there was significant difference between group B and group A in clinical improvement (P <0.05). Conclusions The combination of alprostadil injection and Shenkang injection in the treatment of stage IV diabetic nephropathy has obvious curative effect.